[
  {
    "ts": null,
    "headline": "Should You Retain Henry Schein Stock in Your Portfolio Right Now?",
    "summary": "Investors are optimistic about HSIC, owing to the strong Henry Schein One performance. However, macro headwinds and fierce competition pose challenges.",
    "url": "https://finnhub.io/api/news?id=572f163c6d3954821c5479e5a771df68375e7317c32f8a9de9bce9ca82030b25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751890620,
      "headline": "Should You Retain Henry Schein Stock in Your Portfolio Right Now?",
      "id": 135786041,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Investors are optimistic about HSIC, owing to the strong Henry Schein One performance. However, macro headwinds and fierce competition pose challenges.",
      "url": "https://finnhub.io/api/news?id=572f163c6d3954821c5479e5a771df68375e7317c32f8a9de9bce9ca82030b25"
    }
  },
  {
    "ts": null,
    "headline": "Absci Appoints Biopharma Leader Mary Szela to Board of Directors",
    "summary": "Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertiseVANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors. With decades of R&D and commercial leadership experience, Ms. Sze",
    "url": "https://finnhub.io/api/news?id=cebcf9fc38a292b91aec43e690cbfec0b2a4dac034b29dc4429c0aa072301e4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751889600,
      "headline": "Absci Appoints Biopharma Leader Mary Szela to Board of Directors",
      "id": 135786042,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertiseVANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors. With decades of R&D and commercial leadership experience, Ms. Sze",
      "url": "https://finnhub.io/api/news?id=cebcf9fc38a292b91aec43e690cbfec0b2a4dac034b29dc4429c0aa072301e4a"
    }
  }
]